Impact of sodium–glucose cotransporter-2 inhibitors on clinical outcomes in patients with type 1 diabetes after dialysis-requiring acute kidney injury: a real-world cohort study
Authors' conclusion
In this study, SGLT-2i use was associated with improved kidney outcomes and reduced all-cause mortality in T1D patients with AKD. These findings suggest potential kidney and survival benefits, warranting further prospective validation.
Study context
- Population
- Adults ≥18 years with T1D after dialysis-requiring acute kidney disease, discharged from hospitals 2012–2024, TriNetX Network614 SGLT2i users matched
- Participants
- 16,680 adults
- Exposure
- SGLT2i users vs non-users
- SGLT-2isn = 614
- Outcome
- All-cause mortality, major adverse kidney events (MAKEs) and MACE, Cox proportional hazards regression
- Follow-up
- Median 1.7 years
Methodological detailspropensity-score matched, real-world, TriNetX Network
- Propensity-score matched
- Real-world
- TriNetX Network
Main finding
As reported in the abstract
SGLT-2is vs Non-usersAdjusted hazard ratio (95% CI)
All-cause mortality
0.49(0.36–0.71)
MAKEs
0.53(0.34–0.82)
MACE; no significant difference
0.86(0.59–1.25)
Observational data: associations, not effects.
Safety
Adverse events
- Genital infections and volume depletion were more frequent with SGLT2i
- No significant increase in DKA, urinary tract infections or hypoglycaemia
Original publication
Impact of sodium–glucose cotransporter-2 inhibitors on clinical outcomes in patients with type 1 diabetes after dialysis-requiring acute kidney injury: a real-world cohort study. Diabetes Res Clin Pract. Published 26 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →